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Abstract

The objectives of this study were to (a) pilot test instruments measuring fatigue and quality of life
(QOL); (b) pilot test an exercise intervention; and (c) estimate the effect size of this intervention
relative to completion of combination therapy, fatigue, QOL, and walking distance in 20 patients
with chronic hepatitis C about to begin interferon alpha and ribavirin treatment. Alpha reliabilities
for both the Schwartz Cancer Fatigue Scale and Hepatitis Quality of Life Questionnaire were
moderately high. Power analyses of all outcome measures indicated a small effect size and sample
size estimate of 30–40 per group to achieve power of N.80.
© 2009 Published by Elsevier Inc.

1. Introduction
The purpose of this article is to report on the results of a
pilot study that examined the feasibility of a moderate home
walking intervention for patients with hepatitis C virus
(HCV) taking interferon alpha and ribavirin in combination.
Outcomes of interest were completion of combination
therapy, fatigue, quality of life (QOL), and walking distance. Progressive home walking was chosen as the
intervention because it is an easy-to-do activity and because
moderate activity has been seen as effective in the amelioration of symptoms and side effects in similar chronic
illness populations.
2. Review of the literature
Armstrong et al. (2006) estimated that approximately
3.2 million U.S. citizens have evidence of chronic HCV
infection. Although persons with HCV may not present with
signs or symptoms for as long as 20 years, they experience
much higher levels of morbidity and mortality as the disease
progresses. Signs of chronic illness include persistent
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elevation of liver enzymes; persistent viremia; and rapid
progression to cirrhosis, decompensation, hepatocellular
carcinoma, and possibly even the need for liver transplantation (Seeff, 1999).
Fatigue was found to be a major symptom for patients
with HCV (Clark, Mahoney, Clark & Erikson, 2002;
Heitkemper, Jarrett, Kurashige, & Carithers, 2001) and as
the most disabling symptom in patients with HCV 6 months
before and 6 months after treatment with interferon (Cotler
et. al., 2000). Goh, Coughlan, Quinn, O'Keane, and Crowe
(1999) studied fatigue in women who are HCV positive.
They found that the perceived functional impact of fatigue
was not significantly different in those with autoimmune
disorders or those treated with antiviral therapy compared
with matched controls.
In patients who are HCV positive taking antiviral
medication, varying “types” of fatigue may occur. Fatigue
may result from a sleep disturbance or a perceived fatigue,
such as the inability to focus or make sense of things. In
addition, fatigue has been associated with anemia, dehydration, and depression. Unlike symptoms associated with other
liver disorders, fatigue associated with hepatitis C diagnosis
or its treatment may be variable and episodic, making coping
with this symptom frustrating (Chopra, 2001).
There are no published studies of the impact of walking
on fatigue associated with HCV, but the chronic illness
literature illustrates the positive effects of structured walking
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interventions on other conditions with similar symptoms. A
16-week exercise program (progressive home walking was
one of many options) showed that postexercise walking
distance increased from baseline and 1 month in patients
with melanoma taking interferon alpha and that exercise in
combination with methylphenidate, as well as alone,
appeared to reduce fatigue and have a positive effect on
cognitive function (Schwartz, Thompson, & Masood, 2002).
Mock et al. (1994) studied female breast cancer survivors
receiving chemotherapy who participated in a walking
program. Compared with matched controls, the exercisers
reported having one half as much fatigue. In a similar study
of patients with breast cancer receiving radiation therapy,
Mock et al. (1997) found that the exercise group scored
significantly higher than do the usual care group on physical
functioning (p = .003) and symptom intensity, particularly
fatigue, anxiety, and difficulty sleeping. Findings concluded
that fatigue was the most frequent and intense subjective
symptom reported.
Regardless of the chronic condition, a baseline for a home
walking exercise prescription begins with reviewing the
results of a purposeful exercise test (Gapinski & Zucker,
2005), and both a 12-minute walk test and a graded exercise
stress test can be used for that purpose. Intensity of physical
activity is defined by the American College of Sports
Medicine (ACSM, 2007) and Centers for Disease Control
(2007) in metabolic equivalent (MET) level or the ratio of
exercise metabolic rate. One MET is equivalent to the energy
expenditure for sitting quietly. Moderate activity is equal to
between 3.0 and 6.0 METs (Hendelman, Miller, Baggett,
Debold, & Freedson, 2000).
The most common form of moderate activity according to
this definition is walking at a moderate or brisk pace of 3 to
4.5 mph on a level surface inside or outside. Using the
ACSM calculations, it should take approximately 20 minutes
to walk 1 mile expending a moderate activity level, and the
ACSM (2007) recommends that physical activity is part of a
healthy lifestyle. To date, research in this area has not
focused on the effects of home walking exercise on the
symptoms associated with HCV-related treatment.
The overall goal of this study was to examine the
feasibility of offering a moderately intensive progressive
home walking program to persons experiencing HCVtreatment-related symptoms.

3. Methods
The objectives of this study were (a) to pilot test
instruments measuring fatigue and QOL; (b) to pilot test
an exercise intervention; and (c) to estimate the effect size of
this intervention relative to completion of combination
therapy, fatigue, QOL, and walking distance. This study used
two Massachusetts sites to recruit 20 participants, one private
gastroenterology practice, and one university-affiliated liver
clinic. Both practices see approximately 30 to 50 chronic

hepatitis C participants per month. We excluded persons
under the age of 18 and those unable to speak or understand
English. Men and women with chronic HCV, about to begin
interferon alpha and ribavirin therapy in combination, and
who had no physical disabilities preventing them from
walking were included in this study. Physicians and nurse
practitioners from each site discussed the study with each
eligible patient and got verbal consent. The patient was then
contacted by the principal investigator, and an appointment
was made for further information and to secure informed
consent. This study was granted University of Massachusetts
Human Subjects' approval and institutional review board's
approval from the two Massachusetts gastroenterology/
hepatology practices.
The study employed a two-group pretest–posttest design.
Once informed consent was obtained, the investigators
randomly assigned participants to exercise (EX) or control
(CT) groups using a standard table of random numbers. Prior
to group assignment, all participants completed questionnaires and a 12-minute walk test (Cooper, 2008). Those
assigned to the EX began a self-paced home walking program
3 weeks prior to beginning combination therapy and ended at
the completion of therapy (24 or 48 weeks or discontinuation
of therapy). Both groups had regular telephone contact with
nurses to answer questions and offer support. Exercisers kept
a weekly journal of their walking distance and duration using
a pedometer, appraised their walking effort using a Borg
scale, and kept track of their pulse immediately after walking.
Incremental increases in walking duration and or distance
were recommended during weekly telephone counseling. All
pretest measures were collected again within 1 week of
cessation of treatment of all participants.
3.1. Measures
A general demographic instrument collected identification and contact information for all participants, baseline
laboratory results including genotype, treatment dose, and
other medications. Other measures, not elaborated here, were
before and after the 12-minute walk test and perceived
exertion. Pretests and posttests of fatigue using the Schwartz
Table 1
Sample characteristics

Gender
Mean age, years
Mean weight, lb
Diagnosis
Genotype, %
1a
1b
2b
3a
4
Completed therapy, %

Control group,
n = 10

Experimental group,
n = 10

80% male
48
174
90% naive,
10% nonresponder

80% male
46
189
80% naive,
20% nonresponder

50
10
20
20

50
10
20
10
10
60

70
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Table 2
Reliability statistics—Schwartz Cancer Fatigue Scale

Table 4
Subscale alpha reliabilities a—HQLQ

Cronbach's α

Cronbach's α based on standardized Items

n of items

.862

.844

6

Note. SPSS Version 12 for Windows (Chicago, IL).

Cancer Fatigue Scale (SCFS) (Schwartz, 1998a) and QOL
using the Hepatitis Quality of Life Questionnaire (HQLQ;
Ware, Bayliss, Mannocchia, & Davis, 1999) were measured
on all participants.
The SCFS is a 6-item multidimensional scale developed
for patients with breast cancer taking chemotherapy. The
total scale's internal consistency reliability has been reported
as N.90 (Schwartz, 1998b). Physical and perceptual scales
were similarly excellent at .88 and .81, respectively. The
HQLQ Version 1998 is a 17-question 56-item questionnaire
composed of the eight subscales of the 36-item Short
Form-36 version 1 and has been previously validated (Ware
et al., 1999). The remaining four subscales are the hepatitis
subscales. Internal consistency for all subscales ranged from
.82 to .93 (Bayliss et al., 1998). Scores are summed, and
means are transformed to a 0–100 scale, with 100 as the best
possible score (e.g., best physical function and best mental
health).
4. Findings
Most participants were treatment-naive genotype 1 men
with an average age of 47 years and 182 lb. Most participants
required 48 weeks of treatment (see Table 1).
Study Objective a was to measure alpha reliabilities for
the SCFS computed on the pretest data for both groups. The
overall alpha for this study with patients with HCV was .844
(see Table 2).
The SCFS is scored by summing the items across a 5-point
Likert scale. Scores range from 5, representing low fatigue,
to a high score of 30. In this study, the pretest mean score
for the CT group was 11.9 and that in the EX group was 10.3.
A few patients stated that they did not know what listless
meant. Apart from the item measuring “helpless,” there were
strong interitem correlations for most of all the other items
(see Table 3).
Table 3
Alpha reliabilities—SCFS—interitem correlation matrix

Tired
Difficulty
thinking
Overcome
Listless
Worn out
Helpless

Tired

Difficulty
thinking

1.00
.636

.636
1.000

.444
.655
.823
.140

.722
.349
.810
.140

Overcome

Listless

Worn
out

.444
.722

.655
.349

.823
.810

.140
.140

1.000
.362
.689
.140

.362
1.000
.610
.195

.689
.610
1.000
.401

.140
.195
.401
1.000

Note. SPSS Version 12 for Windows.
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Physical function = .941
Physical role = .853
Bodily pain = .706
General health = .831
Vitality = .879
Social function = .572
a

Role emotional = .896
Mental health = .885
Health distress = .948
Positive well-being = .780
Hepatitis limitations = .960
Hepatitis distress = .963

SPSS Version 12 for Windows.

The HQLQ is composed of 12 subscales. Certain
challenges were presented by 3 subscales. The bodily
function subscale had questions with two different Likert
scales (range = 1–5 and 1–6). The pain subscale questions
asked the respondent to report severity of pain on a 6-point
scale and the amount of interference with normal work.
These questions did not apply to all respondents as many did
not have pain, and a few participants were unemployed. The
social function scale measures how much time and to what
extent one's emotional and physical problems have interfered with normal social activities with family and friends
and to what extent one is limited in those activities. Analysis
of the interitem correlations for this subscale described
negative correlations between Questions 10 and 13. Question
10 asked, “how much of the time have your physical and
emotional problems interfered with social activities?” and
Question 13 asked, “compared to others your age, were your
social activities more or less limited due to your physical and
emotional problems?” Roughly 60% of the sample
responded that they had good social functioning. Analyses
of the positive well-being subscale eliminated one item due
to no variability. The remaining 8 HQLQ subscales had
excellent reliabilities (see Table 4).
Study Objective b was to pilot test the walking
intervention. Dropout rates were 30% and 40% in the CT
and EX groups, respectively. Reasons for dropout included
medical termination of therapy for severe interferon-related
symptoms, relapse to pretreatment behaviors, and being lost
to follow-up.
Study Objective c sought to determine the effect size of
the intervention relative to the outcome variables completion
of therapy, distance walked, and fatigue. Posttest scores were
used for these analyses using Solo Power (BMDP, Los
Angeles, CA) analysis. To achieve a power of .80 or greater,
the sample in a future study must have at least 30 or more
participants per group (see Table 5).

Helpless
Table 5
Prediction of sample size based on the effect size for the completion of
therapy, distance walked, and fatigue

Outcome a: completion of therapy
Outcome b: distance walked, 12-minute walk test
Outcome c: SCFS
a

Predicted n

Power a

30
30
30

.83
1.0
.86

α = .05, SOLO Power analysis (effect size b .30).
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Table 6
Effect size—HQLQ subscales

Physical function
Physical role
Bodily pain
General health
Vitality
Social function
Emotional role
Mental health
Well-being
Health distress
Hepatitis distress
Hepatitis limitations
a

6. Summary
Predicted n

Power a

20
30
50
40
30
10
20
30
40
20
20
20

.88
.87
.76
.85
.87
1.0
.92
.87
.80
1.0
.99
.88

α = .05, SOLO Power (effect size b .20).

Effect size for the intervention relative to the HQLQ
was calculated for each of the transformed subscales.
Predicted sample sizes ranged from 10 to 40 participants. Small effect sizes ranging from .20 or less were
reported (Table 6).

Nursing care of patients undergoing treatment of chronic
hepatitis C requires close attention and follow-up. More
research is needed to support the assumption that there is a
relationship between adherence to therapy, good outcomes of
treatment, and minimization of side effects of treatment
(Gish, 2006). In this study, fatigue was a prominent side
effect of treatment for most participants. Nursing coaching
during moderate walking exercise was seen as a necessary
component of exercisers' success. Results of this study
reinforce the importance of attending to the symptoms
associated with treatment. We found that a home walking
intervention was feasible and low cost, and dropout rates
were consistent with national data.
Walking activity has been seen as a helpful adjunct to
staying healthy in select chronic illness populations. Before a
larger scale study is proposed, further exploratory work
using surveys and focus groups might be helpful to elicit
descriptions of QOL and tailor leisure activity for patients
with hepatitis C who are treatment naive and have relapsed
or not responded to treatment.

5. Discussion of findings
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